The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1519
April 24, 2017
View Complete Issue         Table of Contents 2019 
Reduction of Cardiovascular Risk with Evolocumab (Repatha)
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.
Reduction of Cardiovascular Risk with Evolocumab (Repatha)
April 24, 2017 (Issue: 1519)
The results of the recently published FOURIER trial have shown a reduction in cardiovascular events with addition of the PCSK9 inhibitor evolocumab (Repatha) to statin therapy in patients with atherosclerotic cardiovascular disease...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App for iOS, Android, and Kindle Fire
  • FREE online per issue CME/CE
Purchase this article:
Title: Reduction of Cardiovascular Risk with Evolocumab (Repatha)
Article code: 1519a
 Electronic, downloadable article - $45


Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.